Miquel Vila

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Targeting programmed cell death in neurodegenerative diseases
    Miquel Vila
    Department of Neurology, Columbia University, 650 West 168th Street, BB 307, New York, New York 10032, USA
    Nat Rev Neurosci 4:365-75. 2003
  2. ncbi L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease
    Kim Tieu
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Ann Neurol 56:51-60. 2004
  3. ncbi Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice
    Dong Kug Choi
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 25:6594-600. 2005
  4. pmc Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage
    Celine Perier
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 102:19126-31. 2005
  5. pmc D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
    Kim Tieu
    Department of Neurology, Columbia University, New York, New York, USA
    J Clin Invest 112:892-901. 2003
  6. pmc NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    Du Chu Wu
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 100:6145-50. 2003
  7. ncbi Pathogenic role of glial cells in Parkinson's disease
    Peter Teismann
    Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA
    Mov Disord 18:121-9. 2003
  8. pmc Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
    Peter Teismann
    Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 100:5473-8. 2003
  9. ncbi MPTP as a mitochondrial neurotoxic model of Parkinson's disease
    Serge Przedborski
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Bioenerg Biomembr 36:375-9. 2004
  10. ncbi Glial cell response: A pathogenic factor in Parkinson's disease
    Du Chu Wu
    Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York, USA
    J Neurovirol 8:551-8. 2002

Research Grants

Collaborators

Detail Information

Publications23

  1. ncbi Targeting programmed cell death in neurodegenerative diseases
    Miquel Vila
    Department of Neurology, Columbia University, 650 West 168th Street, BB 307, New York, New York 10032, USA
    Nat Rev Neurosci 4:365-75. 2003
  2. ncbi L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease
    Kim Tieu
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Ann Neurol 56:51-60. 2004
    ..This study demonstrates that HADH II/ABAD modulates MPTP neurotoxicity and suggests that HADH II/ABAD mimetics may provide protective benefit in the treatment of PD...
  3. ncbi Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice
    Dong Kug Choi
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 25:6594-600. 2005
    ..This study demonstrates that MPO participates in the MPTP neurotoxic process and suggests that inhibitors of MPO may provide a protective benefit in PD...
  4. pmc Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage
    Celine Perier
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 102:19126-31. 2005
    ..This molecular scenario may have far-reaching implications for the development of effective neuroprotective therapies for these incurable illnesses...
  5. pmc D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
    Kim Tieu
    Department of Neurology, Columbia University, New York, New York, USA
    J Clin Invest 112:892-901. 2003
    ..Because of the safety record of ketone bodies in the treatment of epilepsy and their ability to penetrate the blood-brain barrier, DbetaHB may be a novel neuroprotective therapy for PD...
  6. pmc NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    Du Chu Wu
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 100:6145-50. 2003
    ..This study supports a critical role for NADPH-oxidase in the pathogenesis of PD and suggests that targeting this enzyme or enhancing extracellular antioxidants may provide novel therapies for PD...
  7. ncbi Pathogenic role of glial cells in Parkinson's disease
    Peter Teismann
    Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA
    Mov Disord 18:121-9. 2003
    ..We discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how those factors may contribute to the pathogenesis of this disease...
  8. pmc Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
    Peter Teismann
    Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 100:5473-8. 2003
    ..Because of the safety record of the COX-2 inhibitors, and their ability to penetrate the blood-brain barrier, these drugs may be therapies for PD...
  9. ncbi MPTP as a mitochondrial neurotoxic model of Parkinson's disease
    Serge Przedborski
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Bioenerg Biomembr 36:375-9. 2004
    ..How mitochondria are affected by MPTP and how their defect contributes to the demise of dopaminergic neurons in this model of PD are discussed in this review...
  10. ncbi Glial cell response: A pathogenic factor in Parkinson's disease
    Du Chu Wu
    Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York, USA
    J Neurovirol 8:551-8. 2002
    ..In this review, the authors discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how these factors may contribute to the pathogenesis of this disease...
  11. ncbi Free radical and nitric oxide toxicity in Parkinson's disease
    Serge Przedborski
    Departments of Neurology and Pathology, Columbia University, New York, New York, USA
    Adv Neurol 91:83-94. 2003
  12. ncbi The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease
    Serge Przedborski
    Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA
    Ann N Y Acad Sci 991:189-98. 2003
    ..How to target these factors to devise effective neuroprotective therapies for PD is also discussed...
  13. ncbi Genetic clues to the pathogenesis of Parkinson's disease
    Miquel Vila
    Department of Neurology, Center for Neurobiology and Behavior, Columbia University, New York, New York 10032, USA
    Nat Med 10:S58-62. 2004
    ..These breakthroughs have not provided a direct explanation for the disease process. Nevertheless, they have helped transform Parkinson's disease research by providing tangible clues to the neurobiology of the disorder...
  14. pmc Neurodegeneration: what is it and where are we?
    Serge Przedborski
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Clin Invest 111:3-10. 2003
  15. pmc Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP
    William Dauer
    Department of Neurology, Columbia University, New York, NY 10027, USA
    Proc Natl Acad Sci U S A 99:14524-9. 2002
    ....
  16. ncbi Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS
    Christelle Guegan
    Department of Neurology, Columbia University, New York, New York 10032, USA
    Mol Cell Neurosci 20:553-62. 2002
    ....
  17. ncbi Interfering with programmed cell death in neurodegenerative diseases: insights from experimental animal models
    Miquel Vila
    Drug Discov Today 9:513-4. 2004
  18. ncbi The rotenone model of Parkinson's disease
    Celine Perier
    Trends Neurosci 26:345-6. 2003
  19. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
    ..This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD...
  20. pmc Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease
    Celine Perier
    Research Institute University Hospital Vall d Hebron, 08035 Barcelona, Spain
    Proc Natl Acad Sci U S A 104:8161-6. 2007
    ..These results provide further insight into the pathogenesis of PD neurodegeneration and identify molecular targets of potential therapeutic significance for this disabling neurological illness...
  21. pmc JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease
    Stephane Hunot
    Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 101:665-70. 2004
    ..Our data revealed that JNK2- and JNK3-induced COX-2 may be a principle pathway responsible for neurodegeneration in PD...
  22. ncbi Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease
    Andreas Hartmann
    INSERM U 289, Hopital de la Salpetriere, 75013 Paris, France
    Neurobiol Dis 10:28-32. 2002
    ..We also show that, ultrastructurally, this effect may be mediated by a redistribution of Bcl-x(L) from the cytosol to the outer mitochondrial membrane...
  23. ncbi Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA
    Isabelle Gourfinkel-An
    INSERM U289, Hopital de la Salpetriere, Paris, France
    J Neurochem 80:466-76. 2002
    ....

Research Grants2

  1. Mechanisms of Bax-mediated cell death in the MPTP model
    Miquel Vila; Fiscal Year: 2003
    ..Collectively, the proposed studies should shed light on the molecular mechanisms of neurodegeneration in PD and help to identify new molecular targets for therapeutic intervention. ..
  2. Mechanisms of Bax-mediated cell death in the MPTP model
    Miquel Vila; Fiscal Year: 2004
    ..Collectively, the proposed studies should shed light on the molecular mechanisms of neurodegeneration in PD and help to identify new molecular targets for therapeutic intervention. ..